Comparison of thrombogenicity in different types of drug‐eluting stents during transition from DAPT to SAPT

Abstract

AbstractBackgroundDuring the transition from dual antiplatelet therapy (DAPT) to single antiplatelet therapy (SAPT), previous studies have raised concerns about a rebound effect. We compared platelet and inflammatory cell adhesion on different types of stents in the setting of clopidogrel presence and withdrawal.MethodsIn Experiment 1, three pigs were administered with DAPT, that is, clopidogrel and acetylsalicylic acid (ASA), for 7 days. Each animal underwent an extracorporeal carotid arteriovenous shunt model implanted with fluoropolymer‐coated everolimus‐eluting stent (FP‐EES), biodegradable‐polymer sirolimus‐eluting stent (BP‐SES), and biodegradable‐polymer everolimus‐eluting stents (BP‐EES). In Experiment 2, two pigs were administered DAPT, clopidogrel was then withdrawn at day 7, and SAPT with ASA was continued for next 21 days. Then flow‐loop experiments with the drawn blood from each time point were performed for FP‐EES, BioLinx‐polymer zotarolimus‐eluting stents (BL‐ZES), and BP‐EES. The rebound effect was defined as the statistical increase of inflammation and platelet adhesion assessed with immunohistochemistry on the stent‐strut level basis from baseline to day‐14 or 28.ResultsBoth experiments showed platelet adhesion value was highest in BP‐EES, while the least in FP‐EES during DAPT therapy. There was no increase in platelet or inflammatory cell adhesion above baseline values (i.e., no therapy) due to the cessation of clopidogrel on the stent‐strut level. Monocyte adhesion was the least for FP‐EES with the same trend observed for neutrophil adhesion.ConclusionsNo evidence of rebound effect was seen after the transition from DAPT to SAPT. FP‐EES demonstrated the most favorable antithrombotic and anti‐inflammatory profile regardless of the different experimental designs.